RxDoctor Payments Data

Susan Winterbauer

Family · Rockford, ILNPI 1073816013

Payments from drug & device makers

$2,631in general payments, 2019–2025

Across 29 payments — averaging $90.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$992
  • Lilly USA, LLC$584
  • Novo Nordisk$436
  • AbbVie$197
  • Insulet Corporation$171
  • Dexcom, Inc.$125
  • plus $126 from 2 others

What the payments were for

  • Food & beverage$2,631100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,631 in reported general payments places this provider in the 85th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$8,215
Medicare patients
46
Services billed
128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide160$237,530
MounjaroTirzepatide111$184,281
EliquisApixaban110$126,414
JardianceEmpagliflozin96$118,825
TrulicityDulaglutide53$94,651
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$66,796
Breztri AerosphereBudesonide/Glycopyr/Formoterol50$63,467
Bevespi AerosphereGlycopyrrolate/Formoterol Fum90$59,010
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr45$38,998
TradjentaLinagliptin28$37,001
LinzessLinaclotide29$33,260
Tresiba Flextouch U-200Insulin Degludec23$31,871
XareltoRivaroxaban25$30,075
RybelsusSemaglutide16$29,421
Stiolto RespimatTiotropium Br/Olodaterol Hcl26$27,789

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$584$278,932164 claims
Novo NordiskOzempic, Rybelsus$436$266,951176 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Farxiga, Symbicort$992$150,393182 claims
AbbVieLinzess$197$33,26029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,941 family providers in Illinois.

Other family in Rockford

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →